Skip to main content
SpringerLink
Log in

Nonbiologic Drugs in Pediatric Rheumatology

  • Chapter
  • First Online:
Pediatric Rheumatology

  • 1621 Accesses

Abstract

The field of pediatric rheumatology has seen a decisive change in the way patients are being treated in last few decades. The diseases of this subspeciality be it JIA, SLE, vasculitis or JDM are chronic and require long term term treatment with drugs. The discovery of new drugs including BRMs and intelligent use of older drugs have made it possible to achieve remission in many of these conditions and provide patients with a better quality of life. This chapter highlights the pharmacology, intended uses and possible adverse side effects of many of these drugs. The information provided in this chapter should be a precursor for treating children with rheumatological illness

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ilowite NT, Laxer RM. Pharmacology and drug therapy. In: Cassidy JT, Petty RE, editors. Text book of pediatric rheumatology. 6th ed. Philadelphia: WB Saunders Company; 2010.

    Google Scholar 

  2. Gilman AG, Brunton LL, Lazo JS, Parker KL. The pharmacologic basis of therapeutics. 11th ed. New York: Pergamon Press; 2005.

    Google Scholar 

  3. Davies NM, Anderson KE. Clinical pharmacokinetics of naproxen. Clin Pharmacokinet. 1997;32:268–93.

    Google Scholar 

  4. Wells TG, Mortensen ME, Dietrich A, Walson PD, Blasier D, Kearns GL. Comparison of the pharmacokinetics of naproxen tablets and suspension in children. J Clin Pharmacol. 1994;34:30–3.

    Google Scholar 

  5. Sellers EM. Plasma protein displacement interactions are rarely of clinical significance. Pharmacology. 1979;18:225–7.

    Google Scholar 

  6. Burgos-Vargas R, Foeldvari I, Thon A, Linke R, Tuerck D. Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis. J Clin Pharmacol. 2004;44:866–72.

    Google Scholar 

  7. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769–72. Erratum in: Lancet 1994; 23;343:1048.

    Google Scholar 

  8. Henry D, Lim LL, Rodriguez GLA, Gutthann PS, Carson JL, Griffin M. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996;312:1563–6.

    Google Scholar 

  9. Mulberg AE, Linz C, Bern E, Tucker L, Verhave M, Grand RJ. Identification of nonsteroidal anti-inflammatory drug-induced gastroduodenal injury in children with juvenile rheumatoid arthritis. J Pediatr. 1993;122:647–9.

    Google Scholar 

  10. Gazarian M, Berkovitch M, Koren G, Silverman ED, Laxer RM. Experience with misoprostol therapy for NSAID gastropathy in children. Ann Rheum Dis. 1995;54:277–80.

    Google Scholar 

  11. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338:727–34.

    Google Scholar 

  12. Yeomans ND, Tulassay Z, Juhász L, Rácz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998;338:719–26.

    Google Scholar 

  13. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85:421–6.

    Google Scholar 

  14. Stéphan JL, Koné-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders. Retrospective study of 24 patients. Rheumatology (Oxford). 2001;40:1285–92.

    Google Scholar 

  15. Schäd SG, Kraus A, Haubitz I, Trcka J, Hamm H, Girschick HJ. Early onset pauciarticular arthritis is the major risk factor for naproxen-induced pseudoporphyria in juvenile idiopathic arthritis. Arthritis Res Ther. 2007;9:R10. PubMed.

    Google Scholar 

  16. Lindsley CB. Uses of nonsteroidal anti-inflammatory drugs in pediatrics. Am J Dis Child. 1993;147:229–36.

    Google Scholar 

  17. Schrör K. Aspirin and Reye syndrome: a review of the evidence. Paediatr Drugs. 2007;9:195–204.

    Google Scholar 

  18. Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum. 1998;41:761–7.

    Google Scholar 

  19. Fauci AS, Dale DC. The effect of hydrocortisone on the kinetics of normal human lymphocytes. Blood. 1975;46:235–43.

    Google Scholar 

  20. Priestley GC, Brown JC. Effects of corticosteroids on the proliferation of normal and abnormal human connective tissue cells. Br J Dermatol. 1980;102:35–41.

    Google Scholar 

  21. Pereira RM, Carvalho JF, Paula AP, Zerbini C, Domiciano DS, Gonçalves H et al.;Committee for Osteoporosis and Bone Metabolic Disorders of the Brazilian Society of Rheumatology; Brazilian Medical Association; Brazilian Association of Physical Medicine and Rehabilitation. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol. 2012;52:580–93.

    Google Scholar 

  22. Kumar S, Rajam L. Posterior reversible encephalopathy syndrome (PRES/RPLS) during pulse steroid therapy in macrophage activation syndrome. Indian J Pediatr. 2011;78:1002–4.

    Google Scholar 

  23. Knox AJ, Mascie-Taylor BH, Muers MF. Acute hydrocortisone myopathy in acute severe asthma. Thorax. 1986;41:411–2.

    Google Scholar 

  24. Laaksonen AL, Sunell JE, Westerén H, Mulder J. Adrenocortical function in children with juvenile rheumatoid arthritis and other connective tissue disorders. Scand J Rheumatol. 1974;3:137–42.

    Google Scholar 

  25. Klein-Gitelman MS, Pachman LM. Intravenous corticosteroids: adverse reactions are more variable than expected in children. J Rheumatol. 1998;25:1995–2002.

    Google Scholar 

  26. Earley A, Cuttica RJ, McCullough C, Ansell BM. Triamcinolone into the knee joint in juvenile chronic arthritis. Clin Exp Rheumatol. 1988;6:153–5.

    Google Scholar 

  27. Ramanan AV, Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child. 2003;88:197–200.

    Google Scholar 

  28. Hashkes PJ, Becker ML, Cabral DA, Laxer RM, Paller AS, Rabinovich CE, Turner D, Zulian F. Methotrexate: new uses for an old drug. J Pediatr. 2014;164:231–6.

    Google Scholar 

  29. Truckenbrodt H, Hafner R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum. 1986;29:801–7.

    Google Scholar 

  30. Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedgwood RJ. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1989;32:677–81.

    Google Scholar 

  31. Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993;20:1845–9.

    Google Scholar 

  32. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F et al.; Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004;50:2191–201.

    Google Scholar 

  33. Vilca I, Munitis PG, Pistorio A, Ravelli A, Buoncompagni A, Bica B, et al.;Pediatric Rheumatology International Trials Organisation (PRINTO). Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Ann Rheum Dis. 2010;69:1479–83.

    Google Scholar 

  34. Albarouni M, Becker I, Horneff G. Predictors of response to methotrexate in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2014;12:35.

    Google Scholar 

  35. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American college of rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84.

    Google Scholar 

  36. Foell D, Frosch M, Schulze zur Wiesch A, Vogl T, Sorg C, Roth J. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? Ann Rheum Dis. 2004;63:206–8.

    Google Scholar 

  37. Rouster-Stevens KA, Ardoin SP, Cooper AM, Becker ML, Dragone LL, Huttenlocher A, Jones KB, Kolba KS, Moorthy LN, Nigrovic PA, Stinson JN, Ferguson PJ, American College of Rheumatology Pediatric Rheumatology Core Membership Group. Choosing wisely: the American college of Rheumatology’s Top 5 for pediatric rheumatology. Arthritis Care Res (Hoboken). 2014;66:649–57.

    Google Scholar 

  38. Wallace CA, Smith AL, Sherry DD. Pilot investigation of naproxen/methotrexate interaction in patients with juvenile rheumatoid arthritis. J Rheumatol. 1993;20:1764–8.

    Google Scholar 

  39. Ravelli A, Caria MC, Buratti S, Malattia C, Temporini F, Martini A. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2001;28:865–7.

    Google Scholar 

  40. Singsen BH, Goldbach-Mansky R. Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders. Rheum Dis Clin North Am. 1997;23:811–40.

    Google Scholar 

  41. Salaffi F, Manganelli P, Carotti M, Subiaco S, Lamanna G, Cervini C. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin Rheumatol. 1997;16:296–304.

    Google Scholar 

  42. Van der Meer A, Wulffraat NM, Prakken BJ, Gijsbers B, Rademaker CM, Sinnema G. Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol. 2007;25:480–5.

    Google Scholar 

  43. Mannion ML, Xie F, Curtis JR, Beukelman T. Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumour necrosis factor inhibitors. J Rheumatol. 2014. pii: jrheum.140012. [Pub ahead of print] PubMed PMID: 25086081.

    Google Scholar 

  44. Fox R. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol. 1998;25 Suppl 53:20–6.

    Google Scholar 

  45. Chickermane PR, Khubchandani RP. Evaluation of the benefits of sequential addition of leflunomide in patients with polyarticular course juvenile idiopathic arthritis failing standard dose methotrexate. Clin Exp Rheumatol. 2015;33:287–92. Epub 2015Feb 18.

    Google Scholar 

  46. Firestein GS, Kelley WN. Kelley’s textbook of rheumatology. Philadelphia: Elsevier/Saunders; 2013.

    Google Scholar 

  47. Behrens F, Finkenwirth C, Pavelka K, Štolfa J, Šipek-Dolnicar A, Thaçi D, Burkhardt H. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res (Hoboken). 2013;65:464–70.

    Google Scholar 

  48. Haibal H, Redwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis. 2005;64:124–6.

    Google Scholar 

  49. Metzler C, Fink C, Lamprecht P, et al. Maintenance of remission with leflunomide in Wegener’s granulomatosis. Rheumatology. 2004;43:315–20.

    Google Scholar 

  50. Metzler C, Fink C, Lamprecht P, et al. Maintenance of remission in Wegener’s granulomatosis: unexpected high relapse rate under oral methotrexate. Ann Rheum Dis. 2005;64 Suppl 3:85.

    Google Scholar 

  51. Tam L, Li E, Wong C, et al. Double-blind, randomized, placebo- controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus. 2004;13:601–4.

    Google Scholar 

  52. Yamazaki T, Miyai E, Shibata H, et al. Pharmacological studies of salazosulfapyridine (SASP) evaluation of anti-rheumatic action. Pharmacometrics. 1991;41:563–74.

    Google Scholar 

  53. Clegg D, Reda D, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies. Arthritis Rheum. 1999;42:2325–9.

    Google Scholar 

  54. Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol. 2006;33:722–31.

    Google Scholar 

  55. Brooks C. Sulfasalazine for the management of juvenile rheumatoid arthritis. J Rheumatol. 2001;28:845–53.

    Google Scholar 

  56. Soriano E, McHugh N. Therapies for peripheral joint disease in psoriatic arthritis: a systematic review. J Rheumatol. 2006;33:1422–30.

    Google Scholar 

  57. Clegg D, Reda D, Weisman M, et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter’s syndrome). Arthritis Rheum. 1996;39:2021–7.

    Google Scholar 

  58. Canadian Hydroxychloroquine Study Group. A randomized study of the effects of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324:150–4.

    Google Scholar 

  59. Toubi E, Rosner I, Rosenbaum M, et al. The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus. 2000;9:92–5.

    Google Scholar 

  60. Erkan D, Yazici Y, Peterson M, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology. 2002;41:924–9.

    Article  CAS  PubMed  Google Scholar 

  61. Espinola R, Pierangeli S, Harris E. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost. 2002;87:518–22.

    CAS  PubMed  Google Scholar 

  62. Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet. 2010;376:1498–509.

    Article  CAS  PubMed  Google Scholar 

  63. Fox R, Dixon R, Guarrasi V, Kruble S. Treatment of primary Sjogren’s syndrome with hydroxychloroquine: a retrospective open-label study. Lupus. 1996;5 Suppl 1:S31.

    Article  PubMed  Google Scholar 

  64. Dawson L, Caulfield V, Stanbury J, et al. Hydroxychloroquine therapy in patients with primary Sjogren’s syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology. 2005;44:449–55.

    Article  CAS  PubMed  Google Scholar 

  65. Olson N, Lindsley C. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol. 1989;16:12.

    Google Scholar 

  66. Marmor M, Carr R, Easterbrook M, et al. Information statement: recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2002;109:1377–82.

    Article  PubMed  Google Scholar 

  67. Browning D. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. Am J Ophthalmol. 2002;133:649–56.

    Article  CAS  PubMed  Google Scholar 

  68. Marmor MF, Kellner U, Lai TY, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;11:415–22.

    Article  Google Scholar 

  69. Haubitz M, Bohnenstengel F, Brunkhorst R, et al. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int. 2002;61:1495–501.

    Article  CAS  PubMed  Google Scholar 

  70. Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener’s granulomatosis. N Engl J Med. 1971;285:1493–6.

    Article  CAS  PubMed  Google Scholar 

  71. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135:248–57.

    Article  CAS  PubMed  Google Scholar 

  72. Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61–4.

    Article  CAS  PubMed  Google Scholar 

  73. Trevisani VF, Castro AA, NevesNeto JF, et al. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus, Cochrane Database Syst Rev. 2006;:CD002265.

    Google Scholar 

  74. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655–66.

    Article  CAS  PubMed  Google Scholar 

  75. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962–70.

    Article  CAS  PubMed  Google Scholar 

  76. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum. 1997;40:2187–98.

    Article  CAS  PubMed  Google Scholar 

  77. Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum. 1998;41:1835–44.

    Article  CAS  PubMed  Google Scholar 

  78. De Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670–80.

    Article  PubMed  Google Scholar 

  79. Virdi RP, Bashir A, Shahzad G, Iqbal J, Mejia JO. Diffuse alveolar hemorrhage: a rare life-threatening condition in systemic lupus erythematosus. Case Rep Pulmonol. 2012;2012:836017. doi:10.1155/2012/836017. Epub 2012 May 27. PubMed PMID: 22934226; PubMed Central PMCID: PMC3420594.

    PubMed  PubMed Central  Google Scholar 

  80. Petri M, Brodsky RA, Jones RJ, et al. High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomised trial. Arthritis Rheum. 2010;62:1487–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Suthanthiran M, Strom TB. Immunoregulatory drugs: mechanistic basis for use in organ transplantation. Pediatr Nephrol. 1997;11:651–7.

    Article  CAS  PubMed  Google Scholar 

  82. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis Hong Kong- Guangzhou Nephrology Study Group. N Engl J Med. 2000;343:1156–62.

    Article  CAS  PubMed  Google Scholar 

  83. Derk CT, Grace E, Shenin M, et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology. 2009;48:1595–9.

    Article  CAS  PubMed  Google Scholar 

  84. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener’s granulomatosis. Arthritis Rheum. 2004;51:278–83.

    Article  CAS  PubMed  Google Scholar 

  85. Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford). 2005;44:386–9.

    Article  CAS  Google Scholar 

  86. Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res. 2010;62:1496–501.

    Article  Google Scholar 

  87. Riskalla MM, Somers EC, Fatica RA, et al. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1508–12.

    CAS  PubMed  Google Scholar 

  88. Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis: a randomized controlled trial. Kidney Int. 2006;70:732–42.

    Article  CAS  PubMed  Google Scholar 

  89. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971–80.

    Article  CAS  PubMed  Google Scholar 

  90. Rahman P, Humphrey-Murto S, Gladman DD, et al. Cytotoxic therapy in systemic lupus erythematosus: experience from a single center. Medicine. 1997;76:432–7.

    Article  CAS  PubMed  Google Scholar 

  91. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behçet’s syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40:769–74.

    Article  CAS  PubMed  Google Scholar 

  92. Jones G, Crotty M, Brooks P. Psoriatic arthritis: a quantitative overview of therapeutic options. The Psoriatic Arthritis Meta-Analysis Study Group. Br J Rheumatol. 1997;36:95–9.

    Article  CAS  PubMed  Google Scholar 

  93. Benenson E, Fries JW, Heilig B, et al. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener’s granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clin Rheumatol. 2005;24:251–7.

    Article  CAS  PubMed  Google Scholar 

  94. Bérezné A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol. 2008;35:1064–72.

    PubMed  Google Scholar 

  95. Szumlanski CL, Honchel R, Scott MC, et al. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver- erythrocyte correlation and presence of isozymes. Pharmacogenetics. 1992;2:148–59.

    Article  CAS  PubMed  Google Scholar 

  96. Mouy R, Stephan JL, Pillet P, et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996;129:750–4.

    Article  CAS  PubMed  Google Scholar 

  97. Caccavo D, Lagana B, Mitterhofer AP, et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum. 1997;40:27–35.

    Article  CAS  PubMed  Google Scholar 

  98. Griffiths B, Emery P, Ryan V, et al. The BILAG multi-centre open randomized controlled trial comparing cyclosporine vs azathioprine in patients with severe SLE. Rheumatology. 2010;49:723–32.

    Article  CAS  PubMed  Google Scholar 

  99. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010;:CD007893.

    Google Scholar 

  100. Lee T, Oh KH, Joo KW, et al. Tacrolimus as an alternative therapeutic option for the treatment of refractory lupus nephritis. Lupus. 2010;19:974–80.

    Article  CAS  PubMed  Google Scholar 

  101. D’Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082–5.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173:699–703.

    Article  CAS  PubMed  Google Scholar 

  103. Lehman TJ, Striegel KH, Onel KB. Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr. 2002;140:125–7.

    Google Scholar 

  104. Sathe K, Khubchandani RP. Thalidomide for systemic onset juvenile idiopathic arthritis. Indian Pediatr. 2013;50:237–9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Manipal Hospital and Indira Gandhi Institute of Child Health, Bangalore, India

    Anand Prahalad Rao

  2. Kasturba Medical College, Manipal University, Mangalore, India

    Nutan Kamath

Authors
  1. Anand Prahalad Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nutan Kamath
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anand Prahalad Rao .

Editor information

Editors and Affiliations

  1. Pediatric Rheumatology Division Institute of Child Health, Sir Ganga Ram Hospital, New Delhi, India

    Sujata Sawhney

  2. Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Amita Aggarwal

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media Singapore

About this chapter

Cite this chapter

Rao, A.P., Kamath, N. (2017). Nonbiologic Drugs in Pediatric Rheumatology. In: Sawhney, S., Aggarwal, A. (eds) Pediatric Rheumatology. Springer, Singapore. https://doi.org/10.1007/978-981-10-1750-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-1750-6_7

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-1749-0

  • Online ISBN: 978-981-10-1750-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation